Hans Prenen

Professor of oncology. I love travelling around the world and am fascinated by science. Passionate about cycling. And now I need a coffee.

[COR2ED @COR2EDMedEd]

📣#GICancer highlights from #ASCO26!

Prof. @HPrenen shares his expert insights on key #ColorectalCancer, #PancreaticCancer & #LiverCancer #trialdata from #EMERALD-3, #BREAKWATER & #RASolute 302

How will these data impact clinical practice? Watch his video to find out!

🤝 Programme endorsed by @WarOnCancer

📺See more updates from @ASCO in 𝘏𝘌𝘙2-mutant #NSCLC, #lungcancer, #ProstateCancer & #BreastCancer
⬇️
https://t.co/KHsgeimvv2

This educational programme is supported by COR2ED
#MedEd #HCC #CRCSM #CRC #CancerNurses

[Annals of Oncology @Annals_Oncology]

1/4 Article of the month: First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase 1 dose exploration. @HPrenen
https://t.co/Nmle5tuQYn

[GI CONNECT powered by COR2ED @giconnectInfo]

Catch the #LowerGI oncology highlights from #ESMO24 📣

👉 https://t.co/ybsrWEpQkT

Profs. @ChiaraCrem1 & @HPrenen explore how new data from a range of trials could impact clinical practice. Don't miss out!

Supported by an independent #MedEd grant from Bayer

[Andreas Brandl @AndreasBrandl8]

Fantastic and insightful lecture from Prof. @HPrenen about
Use of immune therapies in GI cancer at #ESSO43

Practice changing news

@ESSOnews @OncoAlert

[Icro Meattini @Icro_Meattini]

Impact of Exercise on Cancer Recurrence and Survival #ESMO24

@OncoAlert #OncoAlert

[Annals of Oncology @Annals_Oncology]

@HPrenen #ESMO24 concomitant paper: @DocSacher presents the First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor at today's Presidential Symposium @HPrenen

[GI CONNECT powered by COR2ED @giconnectInfo]

🚨 New #LowerGI cancer data from #ESMO24 🚨

Profs. @ChiaraCrem1 & @HPrenen joined us at the congress to each share their insights on new rectal & colorectal cancer data from NICHE-2, NICHE-3 & IMHOTEP trials.

📺Watch their video update

Supported by Bayer #Meded #CRC

[GI CONNECT powered by COR2ED @giconnectInfo]

📣 New #LowerGI cancer data from #ESMO24 📣

Profs. @ChiaraCrem1 & @HPrenen joined us at the congress to share their insights on new data from POD1UM-303/InterAACT 2, RAMTAS/IKF643 & POCHI trials.

📺Watch their video update

Supported by Bayer #Meded #CRC

[Annals of Oncology @Annals_Oncology]

📢 #ESMO24 concomitant paper: First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase 1 dose exploration. #ESMO24 @HPrenen
https://t.co/Nmle5tvoNV

[Lizzy Smyth @LizzySmyth1]

Time to move away from radiotherapy in operable GEA #ESMO24

TOPGEAR ➡️ no survival benefit when RT added to periop chemo

TOPGEAR + ESOPEC : both great trials with a definitive answer = no more RT

✅Great drugs in development - let's focus on systemic Rx for cure @myESMO

[GI CONNECT powered by COR2ED @giconnectInfo]

Are you excited for #ESMO24 and the emerging data in GI oncology?

Lower GI experts, @ChiaraCrem1 and @HPrenen, will be covering the most hotly anticipated data, including the POD1UM-303 study

Watch this space for more over the coming weeks!

[Dr. Luc Colemont @LucColemont]

Hoewel het voor darmkanker slechts in beperkt aantal gevallen (< 10%) werkt is #immuuntherapie toch zeer grote doorbraak in behandeling kanker! 🍀💪🏻

Prof @HPrenen diensthoofd oncologie @UZAnieuws @UAntwerpen legt alles mooi uit in @HLN_BE 😉

@StopDarmkanker 💙 #kennisdelen

[Tim Bolton @TimBolton1981]

Who made this? 😂

[Laure-Anne Teuwen @lateuwen]

If you are working in the field of GI Cancers and Global Oncology, we invite you to submit to the Article Collection "Treating GI cancers in resource-restricted countries" in Gastrointestinal Oncology: Management and Care. https://t.co/2GLpXXVprr @HPrenen @AORTIC_AFRICA

[gilberto lopes @GlopesMd]

Alright! It’s that time of the year again. #ASCO24 is about to start. Here are our now classic rules of engagement. (Still don’t know the author to quote and credit). As usual @VoglNY is exempt. @asco @oncoalert @n8pennell @NarjustFlorezMD @Latinamd @DrSGraff @cancermd @mtmdphd @oncology_bg @GlopesMd @SylvesterCancer @JTrentMDPhD #trentselfie @EmilyJonczak @CharuAggarwalMD @montypal @DrChoueiri @ADesaiMD @neerajaiims @OphiraG @COlazagasti @SamuelKareffMD @OncoAlert

[Hans Prenen @HPrenen]

@spelmanser @bouwspiegel Ik zal mij dan maar omscholen tot huisarts, vooral de dondernamiddag fietsdag spreekt mij aan :)

[Belgian Society of Medical Oncology @mybsmo]

Another great submission for the @mybsmo #bsmoxmas Jumper Xmas Campaign by the oncology team from @UZAnieuws @HPrenen @TimonV @lateuwen @A_Verbiest #SevilayAltintas and others
🇧🇪 ⭐️🧑‍🎄🎄📸 @Stkstichting

[Hans Prenen @HPrenen]

@JDekervel @CappuynsSarah @LambrechtsDlab Nice paper!

[Hans Prenen @HPrenen]

@BoydSwinburn @drkiwicj Very disappointed ! Was so proud of NZ.

[GI CONNECT powered by COR2ED @giconnectInfo]

A panel of GI oncologists discuss the emerging data likely to impact clinical practice

Watch the recorded discussion here 👉https://t.co/TpEZ0F7hTH

Organised in partnership with @eChinaHealth and GI CONNECT members @ModestDominik @HPrenen
#MedEd